South Korean biotech ABION says its MET tyrosine kinase inhibitor spurred a 52.9% overall response rate in a small study involving 17 patients with non-small cell lung cancer that exhibit the MET Exon 14 skipping mutation. For the eight treatment-naïve patients, the ORR was even higher at 75%. According to ABION, c-MET is the most common mutation shown by NSCLC patients after treatment with EGFR TKIs, and it’s looking to start a Phase II combination trial. Its drug, ABN401, can potentially be paired with EGFR drugs, chemotherapy, KRAS or immunotherapies, ABION said. — Amber Tong
